Neoplasms, Fibroepithelial: Clinical Trials

16 trials for Neoplasms, Fibroepithelial, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 active not recruiting, 2 terminated, 1 unknown. 16 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Completed 11, Active not recruiting 2, Terminated 2, Unknown 1
Phase 12Active not recruiting 1, Completed 1

Follow Neoplasms, Fibroepithelial: new trials by email Literature Review of Neoplasms, Fibroepithelial trials Research Report on Neoplasms, Fibroepithelial

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia
pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia., Tamoxifen - Breast Fibroadenoma
Phase 2CompletedMansoura University642018-08-152019-03-07
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Phase 2TerminatedM.D. Anderson Cancer Center92017-05-052024-03-13
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites
Phase 2CompletedUniversity of Chicago1112015-02-252026-03-27
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)1242014-07-212026-11-13
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Phase 1 / Phase 2Active not recruitingMayo Clinic342014-04-252026-08-24
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 2CompletedCelgene2972012-10-312019-09-26
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Phase 2CompletedGOG Foundation582010-12-132021-10-20
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Phase 2CompletedM.D. Anderson Cancer Center332010-04-142022-10-28
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
belinostat, carboplatin - Brenner Tumor, Fallopian Tube Cancer
Phase 2CompletedNational Cancer Institute (NCI)292009-12-012019-07-23
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
Phase 2CompletedGynecologic Oncology Group312009-07-012019-01-15
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis - Brenner Tumor, Fallopian Tube Cancer
Phase 2CompletedUniversity of Washington212006-05-012017-08-28
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
carboplatin, paclitaxel, cytoreductive surgery - Fallopian Tube Cancer, Ovarian Cancer
Phase 2TerminatedMasonic Cancer Center, University of Minnesota72005-10-012017-12-28
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
pegfilgrastim, carboplatin, docetaxel - Fallopian Tube Cancer, Ovarian Cancer
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center2004-06-012010-09-21
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
paclitaxel, carboplatin, erlotinib - Brenner Tumor, Fallopian Tube Cancer
Phase 2CompletedNational Cancer Institute (NCI)562003-04-012015-12-01
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Imatinib mesylate - Life Threatening Diseases
Phase 2CompletedNovartis Pharmaceuticals1852001-02-012016-11-18
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
carboplatin, oglufanide disodium, paclitaxel - Ovarian Cancer, Primary Peritoneal Cavity Cancer
Phase 2UnknownCytran2001-01-012013-11-06

Narrower conditions

Brenner Tumor (15)  ·  Fallopian Tube Neoplasms (13)  ·  Ovarian Neoplasms (9)  ·  Carcinoma, Ovarian Epithelial (8)  ·  Adenocarcinoma (1)  ·  Carcinoma, Adenoid Cystic (1)  ·  Carcinoma, Ductal, Breast (1)  ·  Carcinoma, Renal Cell (1)  ·  Chondrosarcoma (1)  ·  Chordoma (1)  ·  Dermatofibrosarcoma (1)  ·  Fibroadenoma (1)  ·  Fibroma (1)  ·  Hemangiopericytoma (1)  ·  Hemangiosarcoma (1)

Broader conditions

Neoplasms by Histologic Type (16)  ·  Neoplasms, Connective Tissue (16)  ·  Neoplasms, Connective and Soft Tissue (16)  ·  Neoplasms, Fibrous Tissue (16)  ·  Neoplasms, Glandular and Epithelial (16)  ·  Adnexal Diseases (15)  ·  Endocrine System Diseases (15)  ·  Female Urogenital Diseases (15)  ·  Female Urogenital Diseases and Pregnancy Complications (15)  ·  Genital Diseases (15)  ·  Genital Diseases, Female (15)  ·  Genital Neoplasms, Female (15)  ·  Gonadal Disorders (15)  ·  Neoplasms (15)

Interventions

Carboplatin (6)  ·  Paclitaxel (6)  ·  Taxes (5)  ·  Bevacizumab (2)  ·  Disulfides (2)  ·  Erlotinib Hydrochloride (2)  ·  Immunoglobulin G (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Cytoreduction Surgical Procedures (1)  ·  Docetaxel (1)  ·  Drug Therapy (1)  ·  Gemcitabine (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  Imatinib Mesylate (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  M.D. Anderson Cancer Center (2)  ·  Celgene (1)  ·  Cytran (1)  ·  Fred Hutchinson Cancer Center (1)  ·  GOG Foundation (1)  ·  Gynecologic Oncology Group (1)  ·  Mansoura University (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Mayo Clinic (1)  ·  Novartis Pharmaceuticals (1)  ·  University of Chicago (1)  ·  University of Washington (1)

Countries

United States (14)  ·  Canada (1)  ·  Egypt (1)  ·  Singapore (1)

Top investigators

Amar Patel, MD (1)  ·  Amit M Oza (1)  ·  Anil K. Sood, MD (1)  ·  Anil Sood (1)  ·  Barbara Goff (1)  ·  Bradley J Monk (1)  ·  Bradley J. Monk, MD (1)  ·  Dan Veljovich, MD (1)  ·  Don Dizon (1)  ·  Evanthia Galanis, MD (1)  ·  Leona A. Holmberg, MD, PhD (1)  ·  Melissa A. Geller, MD (1)  ·  Michael Gold (1)  ·  Michael Heinrich, MD (1)  ·  Pamela Paley, MD (1)

Results publications

PMID 19451433, PMID 20837357, PMID 28453702, PMID 30309721, PMID 33485453, PMID 37185961, PMID 37407274

NIH funding

U10CA027469 (3), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM62204 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), U10CA180821 (1), U10CA180868 (1), UM1CA186644 (1), UM1CA186705 (1)